Previous 10 | Next 10 |
2023-04-25 08:21:25 ET The following slide deck was published by Novartis AG in conjunction with their 2023 Q1 earnings call. For further details see: Novartis AG 2023 Q1 - Results - Earnings Call Presentation
2023-04-25 08:00:00 ET Summary Phathom Pharmaceuticals, Inc. received a pair of CRLs that look fairly resolvable. If resolved, Phathom Pharmaceuticals will have vonoprazan launch in two indications, one very large, in Q4. They should have enough cash and loans to survive until...
2023-04-25 04:58:57 ET Novartis ( NYSE: NVS ) is trading higher premarket on Tuesday after Q1 results beat estimates and the company raised its FY23 sales outlook. Q1 Core EPS rose +17% on US$ basis (+25% constant currency - cc basis) Y/Y to $1.71. Group net sales grew +...
2023-04-25 01:05:12 ET Novartis press release ( NYSE: NVS ): Q1 Non-GAAP EPS of $1.71 beats by $0.18 . Revenue of $12.95B (+3.4% Y/Y) beats by $350M . Core operating income was $4.4B (+8%, +15% cc) driven by mainly higher gross margin partly offset by higher ot...
2023-04-24 12:22:25 ET Novartis AG ( NYSE: NVS ) ADRs rose to reach a new 52-high on Monday as investors look for updates on the company's strategic turnaround when the Swiss pharma giant releases its Q1 2023 results before the markets open on Tuesday. Wall Street projects the m...
2023-04-23 12:00:00 ET Biotech deal-making is on a roll, with more than $12B worth of transactions announced over the past week alone, and, according to industry observers, the trend is expected to continue in 2023, supported by macro and certain industry-specific factors. Days after Me...
2023-04-21 13:45:05 ET Summary Shares of CRISPR-Cas9 genomic editor Intellia Therapeutics, Inc. have retreated over 80% since hitting an all-time intraday high of $202.73 in late June 2021. Despite the pullback, very early returns suggest a functional cure for HAE and (possibly) A...
2023-04-21 13:30:41 ET The peak of earnings season progresses over the final full week of April. A host of Big Tech heavyweights will garner the most attention, although a wide variety of consumer staples, industrial and energy names are scheduled to provide earnings updates as well. Mi...
The company’s highly experienced and successful pharmaceutical industry leadership team includes former senior executives from Novartis, GSK, and Bristol-Myers Squibb The team has executed eight clinical trials, including a seven-country, 12,400-participant Phase 3 trial of a prior influ...
2023-04-20 06:31:38 ET Novartis ( NYSE: NVS ) said early and continuous treatment with Kesimpta for up to five years in patients with relapsing multiple sclerosis (RMS) showed fewer disability worsening events and low brain volume change versus those who started on Sanofi's Aub...
News, Short Squeeze, Breakout and More Instantly...
2024-07-19 04:04:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
2024-07-18 16:45:16 ET Image source: The Motley Fool. Novartis Ag (NYSE: NVS) Q2 2024 Earnings Call Jul 18, 2024 , 8:00 a.m. ET Operator Continue reading For further details see: Novartis Ag (NVS) Q2 2024 Earnings Call Transcript
2024-07-18 14:15:34 ET By most standards shares of drugmaker Novartis (NYSE: NVS) should be higher following this morning's release of its second-quarter results. The drugmaker's top and bottom lines were both better than expected, and up from year-earlier comparisons. And profit gu...